S

Santhera Pharmaceuticals Holding AG
SIX:SANN

Watchlist Manager
Santhera Pharmaceuticals Holding AG
SIX:SANN
Watchlist
Price: 12.58 CHF 0.8% Market Closed
Market Cap: 133.6m CHF
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

SANN Price Targets Summary
Santhera Pharmaceuticals Holding AG

Wall Street analysts forecast SANN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SANN is 25.5 CHF with a low forecast of 25.25 CHF and a high forecast of 26.25 CHF.

SANN Lowest Forecast
Wall Street Target
25.25 CHF
101% Upside
SANN Average Forecast
Wall Street Target
25.5 CHF
103% Upside
SANN Highest Forecast
Wall Street Target
26.25 CHF
109% Upside
Lowest
Price Target
25.25 CHF
101% Upside
Average
Price Target
25.5 CHF
103% Upside
Highest
Price Target
26.25 CHF
109% Upside
Santhera Pharmaceuticals Holding AG Competitors:
Price Targets
002007
Hualan Biological Engineering Inc
21% Upside
IKT
Inhibikase Therapeutics Inc
292% Upside
B
2480
Beijing Luzhu Biotechnology Co Ltd
44% Upside
LGND
Ligand Pharmaceuticals Inc
43% Upside
002007
Hualan Biological Engineering Inc
21% Upside
IKT
Inhibikase Therapeutics Inc
292% Upside
B
2480
Beijing Luzhu Biotechnology Co Ltd
44% Upside
LGND
Ligand Pharmaceuticals Inc
43% Upside
4
4BB
4Basebio PLC
56% Upside
TSVT
2Seventy Bio Inc
2% Upside

Revenue
Forecast

Revenue Estimate
Santhera Pharmaceuticals Holding AG

For the last 8 years the compound annual growth rate for Santhera Pharmaceuticals Holding AG's revenue is 9%. The projected CAGR for the next 3 years is 60%.

9%
Past Growth
60%
Estimated Growth
Estimates Accuracy
11%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Santhera Pharmaceuticals Holding AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
18%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Santhera Pharmaceuticals Holding AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-85%
Average Miss
What are analyst estimates?

See Also

Summary
SANN intrinsic value, competitors valuation, and company profile.
DCF Valuation
SANN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SANN stock valuation using valuation multiples.
Wall Street Estimates
SANN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SANN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SANN's stock price target?
Price Target
25.5 CHF

According to Wall Street analysts, the average 1-year price target for SANN is 25.5 CHF with a low forecast of 25.25 CHF and a high forecast of 26.25 CHF.

What is Santhera Pharmaceuticals Holding AG's Revenue forecast?
Projected CAGR
60%

For the last 8 years the compound annual growth rate for Santhera Pharmaceuticals Holding AG's revenue is 9%. The projected CAGR for the next 3 years is 60%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.